Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|The Lancet|2021Cited by 337
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre studyKim Linton, Julie M. Vose, Pieternella J. Lugtenburg et al.|The Lancet Haematology|2024Cited by 134
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation DataMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|Blood|2020Cited by 64
Epcoritamab SC Monotherapy Leads to Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: First Data Disclosure from the Epcore NHL-1 Follicular Lymphoma Dose-Expansion CohortKim Linton, Catherine Thiéblemont, Wojciech Jurczak et al.|Blood|2023Cited by 38
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based studyTrine Trab, Kirsten Grønbæk, Iman Chanchiri et al.|Blood Neoplasia|2025Cited by 4